8-K - Denali Therapeutics Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Denali Therapeutics Inc. announced U.S. FDA accelerated approval of AVLAYAH™ (tividenofusp alfa-eknm) for neurologic manifestations in presymptomatic or symptomatic pediatric patients weighing at least 5 kg with Hunter syndrome (MPS II) prior to advanced neurologic impairment. This marks the first FDA-approved therapy designed to cross the blood-brain barrier using the company's TransportVehicle™ platform.

Key Takeaways

1U.S. FDA granted accelerated approval for AVLAYAH on March 25, 2026.

2AVLAYAH indicated for neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients ≥5 kg prior to advanced impairment.

3Phase 1/2 trial showed 91% reduction (95% CI: 89%, 92%) in CSF HS levels by week 24; 93% of treated patients had normal levels.

4First new FDA-approved treatment for Hunter syndrome in nearly 20 years.

5FDA awarded Rare Pediatric Disease Priority Review Voucher (PRV) in connection with approval.

6Ongoing Phase 2/3 COMPASS study to confirm clinical benefit.

Current Report Details

Event Type

Regulation Fd

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

by reference. The information furnished in this Item 7.01 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of

Regulation Fd

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated March 25, 2026 104 Cover Page Interactive Data File (formatted

Exhibits Only

Exhibits (1)

8-K